Bicillin C-R

Bicillin C-R

 [bi-sil´in]
trademark for combination preparations of the antibiotics penicillin g benzathine and penicillin g procaine.

Bicillin C-R

[bi-sil′in]
a trademark for combination preparations of the antibiotics penicillin G benzathine and penicillin G procaine.
References in periodicals archive ?
and the Food and Drug Administration are warning physicians about the inappropriate use of Bicillin C-R (penicillin G benzathine and penicillin G procaine injectable suspension) for the treatment of syphilis.
The company has received postmarketing reports from several STD clinics in the United States where Bicillin C-R was used instead of Bicillin L-A to treat patients with syphilis.
The company is changing the packaging and syringe labels of Bicillin C-R to highlight the distinction between that product and Bicillin L-A.
Bicillin C-R is marketed by Wyeth-Lederle Vaccines and Pediatrics, a division of Wyeth-Ayerst Laboratories.
Bicillin C-R products are indicated for treatment of moderately severe to severe infections of the upper respiratory tract, such as pharyngitis (strep throat) caused by group A beta-hemolytic streptococci (GABHS).
The Bicillin family of products includes Bicillin C-R 900/300 Injection (900,000 units penicillin G benzathine and 300,000 units penicillin G procaine suspension) and Bicillin C-R Injection (600,000 units penicillin G benzathine and 600,000 units penicillin G procaine suspension).